PTGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Protagonist Therapeutics Inc (PTGX) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show bullish momentum and analysts have raised price targets with positive expectations for 2026, the company's financial performance is weak, with significant revenue and net income declines. Additionally, the recent exit of a major institutional investor (BVF) raises concerns about confidence in the stock. The options data also suggests low bearish sentiment, but the lack of strong proprietary trading signals or recent congress trading data further supports a cautious approach.
The technical indicators for PTGX are bullish. The MACD is positive and expanding, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm an uptrend. The RSI is at 77.683, which is neutral but nearing overbought levels. The stock is trading near its resistance level (R1: 88.479), with potential upside to R2: 91.45. However, the stock's historical trend suggests a likelihood of minor declines in the short term.
The company's gross margin remains strong at 100%, and cash reserves have increased to $646M, providing financial flexibility.
EPS also fell sharply (-134.85%). Additionally, BVF's complete exit from its stake in PTGX raises concerns about institutional confidence. The stock's historical trend suggests potential short-term declines.
In Q4 2025, Protagonist Therapeutics reported revenue of $7.44M, a significant YoY drop of -95.64%. Net income fell to -$44.38M (-133.71% YoY), and EPS dropped to -$0.69 (-134.85% YoY). Despite these declines, the company increased its cash reserves to $646M and maintained a gross margin of 100%.
Analysts are bullish on PTGX, with multiple firms raising price targets recently (e.g., Barclays to $113, Citizens to $112, H.C. Wainwright to $117). Analysts cite the company's strong drug development pipeline and upcoming regulatory approvals as key drivers for future growth. However, the firm's financial performance and institutional investor confidence remain concerns.
